ASCO GU 2022 - Results from #180

Viewing 181-200 of 316 articles

ASCO GU 2022: Outcomes According to Histological Variants of Urothelial Carcinoma After Neoadjuvant Chemotherapy in the GETUG-AFU V05 VESPER Trial

ASCO GU 2022: Safety Lead-in of Phase II SBRT and Durvalumab with or Without Tremelimumab for Unresectable and Cisplatin-Ineligible, Locally Advanced or Metastatic Bladder Cancer

ASCO GU 2022: Tailored Immunotherapy Approach with Nivolumab in Advanced Transitional Cell Carcinoma (TITAN-TCC)

ASCO GU 2022: BAYOU: A Phase II, Randomized, Multicenter, Double-Blind, Study of Durvalumab in Combination With Olaparib for the First-Line Treatment of Platinum-Ineligible Patients With Unresectable, Stage IV Urothelial Carcinoma

ASCO GU 2022: A Randomized, Double Blind, Biomarker Selected, Phase II Clinical Trial of Maintenance PARP Inhibition Following Chemotherapy for Metastatic Urothelial Carcinoma: Final Analysis of the ATLANTIS Rucaparib Arm

ASCO GU 2022: NEXT: A Single-Arm, Phase 2, Open-Label Study of Adjuvant Nivolumab After Completion of Chemo-Radiation Therapy in Patients With Localized Muscle-Invasive Bladder Cancer

ASCO GU 2022: Vesical Imaging-Reporting and Data System (VI-RADS)

ASCO GU 2022: Genomic Characterization of Patients With De-Novo High-Volume Metastatic Castration-Sensitive Prostate Cancer Compared to Those Without

ASCO GU 2022: Quantifying Molecular Imaging Patterns of Treatment Response or Progression Using a Novel Traffic Light Workflow Within a Prospective Phase I/II Trial of 177LuPSMA-617 and NOX66 (LuPIN)

ASCO GU 2022: Survival Outcomes and Characterization of Patients With Metastatic Castration-Sensitive Prostate Cancer Undergoing Intensified ADT Who Do Not Achieve an Optimal PSA Response (PSA ≤0.2 Ng/ML)

ASCO GU 2022: Serial ctDNA Evaluation to Predict Clinical Progression in Patients with Advanced Urothelial Carcinoma

ASCO GU 2022: Clinical Implications of Molecular Biomarkers in Upper-Tract Urothelial Carcinoma

ASCO GU 2022: Implementation of PSMA-PET in Focal Dose-Escalated Radiotherapy of Primary Prostate Cancer Patients: Results of a Planned Safety Analysis of a Phase II Trial

ASCO GU 2022: Phase 2 Randomized Trial of ModraDoc006/R, Oral Docetaxel Plus Ritonavir, Versus Intravenous Docetaxel in Metastatic Castration Resistant Prostate Cancer

ASCO GU 2022: Tumor Mutational Burden as a Predictive Biomarker for Immune Checkpoint Inhibitor Versus Taxane Chemotherapy Benefit in Metastatic Castration-Resistant Prostate Cancer: A Real-World Biomarker Study

ASCO GU 2022: MiCheck Prostate Blood Test for Aggressive Prostate Cancer Designed for the Clinical Lab Setting

ASCO GU 2022: TROPHY-U-01 Cohort 3: Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer Who Progressed After Platinum-Based Regimens

ASCO GU 2022: Study EV-103 Cohort H: Antitumor Activity of Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Patients with MIBC Who Are Cisplatin Ineligible

ASCO GU 2022: Comprehensive Molecular Characterization of MIBC Treated with Durvalumab plus Olaparib in the Neoadjuvant Setting: Neodurvarib Trial

ASCO GU 2022: Defining Hereditary Upper Tract Urothelial Carcinoma: Implications for Genetic Testing and Clinical Management

5
6
7
8
9
10
11
12
13
14